253 related articles for article (PubMed ID: 20546778)
21. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Capranzano P; Ferreiro JL; Angiolillo DJ
Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
[TBL] [Abstract][Full Text] [Related]
22. Novel antiplatelet therapy.
Gaglia MA; Manoukian SV; Waksman R
Am Heart J; 2010 Oct; 160(4):595-604. PubMed ID: 20934552
[TBL] [Abstract][Full Text] [Related]
23. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Romero-Barra M; Camoin L; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
Thromb Haemost; 2007 Feb; 97(2):212-7. PubMed ID: 17264949
[TBL] [Abstract][Full Text] [Related]
24. Effects of ticlopidine on von Willebrand factor-mediated shear-induced platelet activation and aggregation.
Goto S; Tamura N; Sakakibara M; Ikeda Y; Handa S
Platelets; 2001 Nov; 12(7):406-14. PubMed ID: 11674857
[TBL] [Abstract][Full Text] [Related]
25. The current state of antiplatelet therapy in acute coronary syndromes: the data and the real world.
Alexander JH
Cleve Clin J Med; 2009 Apr; 76 Suppl 1():S16-23. PubMed ID: 19332589
[TBL] [Abstract][Full Text] [Related]
26. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A
J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369
[TBL] [Abstract][Full Text] [Related]
27. Prasugrel: Clinical development and therapeutic application.
Guerra DR; Tcheng JE
Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231
[TBL] [Abstract][Full Text] [Related]
28. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Mousa SA; Jeske WP; Fareed J
Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
[TBL] [Abstract][Full Text] [Related]
29. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
[TBL] [Abstract][Full Text] [Related]
30. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination.
Cooke GE; Liu-Stratton Y; Ferketich AK; Moeschberger ML; Frid DJ; Magorien RD; Bray PF; Binkley PF; Goldschmidt-Clermont PJ
J Am Coll Cardiol; 2006 Feb; 47(3):541-6. PubMed ID: 16458133
[TBL] [Abstract][Full Text] [Related]
31. Common variations in platelet glycoproteins: pharmacogenomic implications.
Quinn MJ; Topol EJ
Pharmacogenomics; 2001 Nov; 2(4):341-52. PubMed ID: 11722284
[TBL] [Abstract][Full Text] [Related]
32. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
[TBL] [Abstract][Full Text] [Related]
33. Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention.
Foo F; Oldroyd KG
Biomark Med; 2011 Feb; 5(1):9-30. PubMed ID: 21319962
[TBL] [Abstract][Full Text] [Related]
34. Antiplatelet agents in acute coronary syndromes.
Sakhuja R; Yeh RW; Bhatt DL
Curr Probl Cardiol; 2010 Mar; 35(3):123-70. PubMed ID: 20152547
[TBL] [Abstract][Full Text] [Related]
35. Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease.
Zeidner JF; Frishman WH; Lerner RG
Cardiol Rev; 2008; 16(5):250-9. PubMed ID: 18708826
[TBL] [Abstract][Full Text] [Related]
36. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
Int J Clin Pract; 2006 Jul; 60(7):863-6. PubMed ID: 16846403
[TBL] [Abstract][Full Text] [Related]
37. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
Bhatt DL
Am J Cardiol; 2009 Feb; 103(3 Suppl):11A-19A. PubMed ID: 19166708
[TBL] [Abstract][Full Text] [Related]
38. Platelets and antiplatelet therapy in patients with diabetes mellitus.
Arjomand H; Roukoz B; Surabhi SK; Cohen M
J Invasive Cardiol; 2003 May; 15(5):264-9. PubMed ID: 12730635
[TBL] [Abstract][Full Text] [Related]
39. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
Harrington RA
Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
[TBL] [Abstract][Full Text] [Related]
40. Prasugrel: a novel platelet ADP P2Y receptor antagonist.
Wilson W; Gurvitch R; Ajani AE
Cardiovasc Ther; 2009; 27(3):194-8. PubMed ID: 19689619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
